



DIVI'S LABORATORIES LTD

DATE- 25 JULY 2024


About Company


Divi's has been established for more than 30 years in Hyderabad, India with two manufacturing units and is among the top pharmaceutical's companies in India. It manufactures Generic APIs, Custom synthesis of APIs & Intermediates along with Nutraceutical Ingredients to the Global Pharmaceutical & Nutraceutical industry through sustainable leadership in chemistry. Divi's is the leading manufacturer of APIs (Active pharmaceuticals ingredients), Intermediates and Registered starting materials offering high quality products with the highest level of compliance and integrity to over 100+ countries.


OUR RECOMMENDATION:

OPTION INSIGHT: BUY DIVISLAB 4550 CALL AUGUST CONTRACT BETWEEN 123-130 TARGETS 150-175 STOP LOSS BELOW 110

MARKET CAP	P/E	DIVIDEND YIELD	ROCE	ROE	-	3YEARS SALES GROWTH	3YEARS PROFIT GROWTH
RS.1,21,538 CR.	75.8	0.66 %	16.5 %	12.2%	2.00	4%	-7%









TECHNICAL ANALYSIS

After trading in consolidation range, the stock has given the breakout of consolidation range in hourly chart, the stock is trading around the 200 EMA (Exponential Moving Average), 55 EMA, and 21 EMA, indicating its present trend and momentum. The SuperTrend indicator is

green, which is a bullish signal. The stock has shown resilience above the support level around Rs 4442.53. If the price continues to hold above the EMAs, it could signal further upward momentum. The rising volume in daily chart and bullish candle indicated an upward momentum. On the basis of above information, we gave a buy signal in Divis Lab 4550 Call option.

DISCLAIMER

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverages my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as noninvestment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.